We are live on
!
Find out more
Royce & Associates Portfolio holdings
AUM
$12.4B
Turnover
20.64%
1-Year Est. Return
64.17%
This Fund
S&P 500
This Quarter
Est. Return
+10.53%
1 Year Est. Return
+64.17%
3 Year Est. Return
+130.04%
5 Year Est. Return
+162.55%
10 Year Est. Return
+785.5%
AUM
$33.6B
AUM Growth
+$1.25B
(+3.9%)
Cap. Flow
-$1.82B
Cap. Flow
% of AUM
-5.43%
Top 10 Holdings %
Top 10 Hldgs %
10.25%
Holding
1,526
New
88
Increased
442
Reduced
565
Closed
79
Avg Time Held
0.2
years
Top 10 Avg Time Held
0.2
years
Top 20 Avg Time Held
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mativ Holdings
MATV
|
+$106M |
| 2 |
Acacia Research
ACTG
|
+$101M |
| 3 |
Universal Corp
UVV
|
+$47.5M |
| 4 |
PARTNERRE LTD
PRE
|
+$41.9M |
| 5 |
Standard Motor Products
SMP
|
+$41.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MOLXA
MOLEX INC CL-A
MOLXA
|
+$314M |
| 2 |
Nu Skin
NUS
|
+$241M |
| 3 |
Lincoln Electric
LECO
|
+$116M |
| 4 |
HITK
HI-TECH PHARMACAL INC
HITK
|
+$64.5M |
| 5 |
Dorman Products
DORM
|
+$56.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 24.94% |
| 2 | Technology | 17.69% |
| 3 | Consumer Discretionary | 14.45% |
| 4 | Financials | 10.27% |
| 5 | Materials | 9.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1376
DELISTED
DEALERTRACK TECHNOLOGIES, INC. COM STK
TRAK
| $73K | ﹤0.01% |
1,700
| – | – |
2013 Q2
1 quarter
|
|
1377
Standard BioTools
LAB
$247M
| $72K | ﹤0.01% |
3,300
| – | – |
2013 Q2
1 quarter
|
|
|
GTAT
1378
DELISTED
GT ADVANCED TECHNOLOGIES INC COM STK (DE)
GTAT
| $72K | ﹤0.01% |
8,500
-11,500
| -58% | -$68.6K |
2013 Q2
1 quarter
|
|
1379
Herc Holdings
HRI
$4.06B
| $71K | ﹤0.01% |
+1,067
| New | +$81.8K |
2013 Q3
0 quarters
|
|
1380
Aware
AWRE
$19.6M
| $70K | ﹤0.01% |
12,800
| – | – |
2013 Q2
1 quarter
|
|
|
TEAR
1381
DELISTED
TearLab Corporation
TEAR
| $70K | ﹤0.01% |
630
-360
| -36% | -$44.9K |
2013 Q2
1 quarter
|
|
1382
Scully Royalty
SRL
$74.6M
| $69K | ﹤0.01% |
1,632
-1,640
| -50% | -$68.6K |
2013 Q2
1 quarter
|
|
1383
Usana Health Sciences
USNA
$287M
| $69K | ﹤0.01% |
1,600
| – | – |
2013 Q2
1 quarter
|
|
|
SCLN
1384
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
| $69K | ﹤0.01% |
13,700
+2,000
| +17% | +$11.1K |
2013 Q2
1 quarter
|
|
1385
Cooper Companies
COO
$11B
| $65K | ﹤0.01% |
+2,000
| New | +$64.5K |
2013 Q3
0 quarters
|
|
1386
DELISTED
PROS Holdings
PRO
| $65K | ﹤0.01% |
1,900
| – | – |
2013 Q2
1 quarter
|
|
|
NDZ
1387
DELISTED
NORDION INC COM STK (CDA)
NDZ
| $65K | ﹤0.01% |
7,530
-38,600
| -84% | -$301K |
2013 Q2
1 quarter
|
|
1388
Johnson Outdoors
JOUT
$455M
| $64K | ﹤0.01% |
2,400
-800
| -25% | -$20.7K |
2013 Q2
1 quarter
|
|
1389
DELISTED
MEADOWBROOK INSURANCE GRP INC
MIG
| $64K | ﹤0.01% |
9,811
-10,100
| -51% | -$72.1K |
2013 Q2
1 quarter
|
|
1390
Cleveland-Cliffs
CLF
$6.91B
| $62K | ﹤0.01% |
+3,000
| New | +$61.7K |
2013 Q3
0 quarters
|
|
1391
Neogen
NEOG
$2.58B
| $61K | ﹤0.01% |
4,000
| – | – |
2013 Q2
1 quarter
|
|
1392
VSE Corp
VSEC
$4.6B
| $61K | ﹤0.01% |
+2,600
| New | +$59.3K |
2013 Q3
0 quarters
|
|
|
OMCC
1393
DELISTED
Old Market Capital Corp
OMCC
| $60K | ﹤0.01% |
3,700
| – | – |
2013 Q2
1 quarter
|
|
|
VASC
1394
DELISTED
Vascular Solutions Inc
VASC
| $60K | ﹤0.01% |
3,600
| – | – |
2013 Q2
1 quarter
|
|
1395
Hartford Financial Services
HIG
$36.6B
| $56K | ﹤0.01% |
1,800
-1,600
| -47% | -$49.9K |
2013 Q2
1 quarter
|
|
|
PHLT
1396
DELISTED
Performant Healthcare Inc
PHLT
| $56K | ﹤0.01% |
5,100
| – | – |
2013 Q2
1 quarter
|
|
|
CKSW
1397
DELISTED
CLICKSOFTWARE TECH LTD
CKSW
| $55K | ﹤0.01% |
+9,100
| New | +$63.3K |
2013 Q3
0 quarters
|
|
1398
Axogen
AXGN
$2.03B
| $53K | ﹤0.01% |
+12,000
| New | +$44.1K |
2013 Q3
0 quarters
|
|
1399
United States Lime & Minerals
USLM
$3.04B
| $53K | ﹤0.01% |
4,500
+1,000
| +29% | +$11.7K |
2013 Q2
1 quarter
|
|
1400
American Vanguard Corp
AVD
$31.3M
| $51K | ﹤0.01% |
1,900
| – | – |
2013 Q2
1 quarter
|
|
Similar funds
Royce & Associates's Q3 2013 Portfolio in Review
As of Q3 2013, Royce & Associates held 1,526 positions worth $33.6B, up 3.9% from $32.4B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Royce & Associates withdrew a net $1.82B in Q3 2013, closing 79 positions and reducing 565 holdings. Its most notable exit was MAIDENFORM BRANDS, INC, an estimated $44.3M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 25% of assets, up from 24% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Royce & Associates opened a new position in Genesco worth $17.8M.
- Royce & Associates's largest Q3 2013 buy was Genesco: 272,129 shares worth $17.8M.
- Royce & Associates added most to Mativ Holdings in Q3 2013, an estimated $106M increase.
- Royce & Associates's biggest Q3 2013 reduction was MOLEX INC CL-A, cutting an estimated $314M.
- Royce & Associates fully exited MAIDENFORM BRANDS, INC in Q3 2013, selling an estimated $44.3M.
- Royce & Associates's ten largest holdings make up 10% of its $33.6B portfolio in Q3 2013.
- Royce & Associates opened 88 new positions and closed 79 in Q3 2013.
- Royce & Associates's portfolio value rose 3.9% quarter-over-quarter to $33.6B.
Based on Royce & Associates's 13F filing for Q3 2013, filed 12 Nov 2013.